Two Sigma Investments LP Buys 45,518 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Two Sigma Investments LP grew its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 21.9% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 252,939 shares of the biopharmaceutical company's stock after acquiring an additional 45,518 shares during the period. Two Sigma Investments LP owned about 0.16% of Ocular Therapeutix worth $2,160,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Atlas Capital Advisors Inc. bought a new stake in Ocular Therapeutix during the fourth quarter worth about $43,000. AlphaQuest LLC purchased a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $53,000. Tower Research Capital LLC TRC boosted its position in shares of Ocular Therapeutix by 2,045.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 8,446 shares in the last quarter. Walleye Capital LLC purchased a new stake in shares of Ocular Therapeutix in the 4th quarter worth approximately $90,000. Finally, XTX Topco Ltd bought a new position in Ocular Therapeutix during the 4th quarter valued at approximately $99,000. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Stock Performance

NASDAQ:OCUL traded up $0.08 during mid-day trading on Thursday, reaching $8.46. The company's stock had a trading volume of 1,923,440 shares, compared to its average volume of 1,405,641. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The stock has a market cap of $1.35 billion, a P/E ratio of -6.41 and a beta of 1.51. The firm's fifty day moving average price is $7.43 and its two-hundred day moving average price is $7.90. Ocular Therapeutix, Inc. has a 12-month low of $4.79 and a 12-month high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. On average, equities analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ocular Therapeutix news, Director Richard L. Md Lindstrom purchased 10,000 shares of Ocular Therapeutix stock in a transaction dated Thursday, May 8th. The stock was purchased at an average price of $6.96 per share, with a total value of $69,600.00. Following the transaction, the director now directly owns 172,704 shares of the company's stock, valued at $1,202,019.84. This trade represents a 6.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pravin Dugel sold 21,219 shares of the firm's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total transaction of $152,352.42. Following the completion of the transaction, the insider now directly owns 3,499,099 shares in the company, valued at approximately $25,123,530.82. The trade was a 0.60% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,079 shares of company stock valued at $208,739. Company insiders own 2.30% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the company. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Thursday, May 29th. Needham & Company LLC lowered their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, May 6th. Royal Bank of Canada started coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price objective on the stock. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. Finally, William Blair started coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They issued an "outperform" rating for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, Ocular Therapeutix presently has an average rating of "Moderate Buy" and a consensus price target of $16.25.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.